QCG
CLDX icon

Quadrant Capital Group’s Celldex Therapeutics CLDX Stock Holding History

Quadrant Capital Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.08K Hold
160
– – ﹤0.01% 2350
2025
Q4 		$4.35K Hold
160
– – ﹤0.01% 2410
2025
Q3 		$4.14K Buy
+160
New +$3.71K ﹤0.01% 2354
2025
Q2 		– Sell
-334
Closed -$6.06K – 1594
2025
Q1 		$6.06K Buy
334
+267
+399% +$5.97K ﹤0.01% 2320
2024
Q4 		$1.69K Buy
+67
New +$1.82K ﹤0.01% 2516
2022
Q3 		– Sell
-132
Closed -$4K – 2653
2022
Q2 		$4K Buy
+132
New +$3.83K ﹤0.01% 2022
2016
Q1 		– Sell
-25
Closed -$5K – 1827
2015
Q4 		$5K Buy
+25
New +$5.45K ﹤0.01% 1077

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return